Innoviva, Inc. (NASDAQ:INVA) Shares Purchased by Texas Permanent School Fund

Texas Permanent School Fund increased its stake in shares of Innoviva, Inc. (NASDAQ:INVAGet Rating) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,339 shares of the biotechnology company’s stock after purchasing an additional 999 shares during the quarter. Texas Permanent School Fund owned 0.07% of Innoviva worth $669,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of INVA. Comerica Bank grew its stake in Innoviva by 2.2% during the 1st quarter. Comerica Bank now owns 55,838 shares of the biotechnology company’s stock worth $1,021,000 after purchasing an additional 1,198 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Innoviva during the 1st quarter worth about $1,344,000. Versor Investments LP acquired a new position in shares of Innoviva during the 1st quarter worth about $534,000. Envestnet Asset Management Inc. boosted its position in shares of Innoviva by 13.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 193,941 shares of the biotechnology company’s stock worth $3,753,000 after acquiring an additional 23,721 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. boosted its position in shares of Innoviva by 3.3% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 161,200 shares of the biotechnology company’s stock worth $3,119,000 after acquiring an additional 5,200 shares in the last quarter.

Innoviva Stock Down 3.2 %

Innoviva stock opened at $13.11 on Tuesday. Innoviva, Inc. has a fifty-two week low of $11.56 and a fifty-two week high of $20.71. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.34 and a current ratio of 2.77. The company has a market capitalization of $914.86 million, a P/E ratio of 4.11 and a beta of 0.59. The stock has a 50-day simple moving average of $12.86 and a 200-day simple moving average of $14.00.

Wall Street Analysts Forecast Growth

INVA has been the subject of several analyst reports. Morgan Stanley upped their price objective on Innoviva from $13.00 to $14.00 and gave the stock an “underweight” rating in a research report on Thursday, October 13th. TheStreet raised Innoviva from a “c” rating to a “b-” rating in a research report on Thursday, November 10th. Finally, StockNews.com began coverage on Innoviva in a research report on Wednesday, October 12th. They set a “buy” rating for the company.

Innoviva Company Profile

(Get Rating)

Innoviva, Inc engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

See Also

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVAGet Rating).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.